Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
View original at globenewswire.comMerck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML Me…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Despite new therapeutic options, there is significant need for innovative, well-tolerated therapies with faster time to onset of molecular response leading to deeper responses and better disease control for chronic myeloid leukemia
60% confidenceBased on early clinical evidence, TERN-701, a novel allosteric BCR::ABL1 inhibitor, may have the potential to provide a meaningfully differentiated option for certain patients living with CML
60% confidenceTERN-701 has shown promising activity in clinical trials to date, with encouraging rates of major molecular response and deep molecular response observed by week 24, including responses in patients with high disease burden who previously received multiple lines of therapy
60% confidenceThe majority of treatment-emergent adverse events for TERN-701 were reported as low grade with a low incidence of severe adverse events and discontinuations, with no clinically meaningful changes in blood pressure and low rates of lipase elevation
60% confidenceThe acquisition of Terns builds on Merck's growing presence in hematology with TERN-701, a potential best-in-class candidate for the treatment of certain patients with chronic myeloid leukemia
60% confidenceBy working together with Merck, Terns will advance TERN-701, leveraging the deep expertise and significant resources at Merck, a global biopharmaceutical leader with a proven track record of delivering cancer breakthroughs
60% confidenceThis transaction further diversifies and strengthens Merck's position in oncology as the company continues to look for opportunities to broaden its portfolio into other therapeutic areas
60% confidence